



CGX

CANCER RISK ASSESSMENT

WHY CHOOSE REDWOOD LABS

Targeted Treatments | Accurate Outcomes

EMR INTEGRATIONS
ACCEPTS MOST INSURANCES

PHLEBOTOMIST AVAILABLE
QUICK TURN AROUND TIME



**ELITE CLINICAL
LABORATORY**

3600 S Gessner Rd Suite 110, Houston, TX 77063

Phone: 281-378-2116 | Fax: 281-466-2483

www.elitelabs.com

The reports and content within should be considered referenced suggestions.
Ultimately, final medical decisions are made by your respective healthcare provider.

COLLECTION GUIDE

SPECIMEN COLLECTION

Step 1

Remove the swabs from wrapper

Step 2

Thoroughly swab BOTH right and left cheeks at least 20 times each.

SUBMISSION

Step 1

Insert the swab into the tube pushing it all the way to the bottom of the tube. Holding the swab shaft close to the rim of the tube and point the tube away, break the swab shaft along the prescored breakpoint indentation.

Step 2

Label the specimen appropriately, including two patient identifiers. (e.g. Patient name and date of birth) Also include specimen source, date and time of collection.

Targeted treatments | Accurate Outcomes BASED ON DNA EVIDENCE

The CGX Screen developed by Redwood Lab, is the first Comprehensive Cancer Risk Assessment test designed to determine your risk of developing up to 8 cancer types. Armed with this critical genetic information as well as other medical and family facts, you can create a strategy to reduce your risk of developing one or more of these 8 prevalent cancers.



AT RISK PATIENTS

- Families with early onset of cancer
- Menstruation / Menopause
- Family history of Cancer
- Mid-age cancer risks
- Personal history of cancer




COMMON SYMPTOMS

- Problems with eating
- Changes in bowel habits
- Breast changes (ie: Lump)
- Skin changes (ie: New mole)
- Difficult or painful urination
- A thickening or lump on or under the skin
- Weight gain or loss with no known reason
- Hoarseness or cough that does not go away



ADVANTAGES

- Test provided in house
- Provides an accurate diagnosis within 7 days
- Providing most clinically significant panel available
- Unaffected by concurrent antibiotic use
- Decreases healthcare costs
- Reduces unnecessary drug exposure and adverse events
- Decreases patient risks
- Eliminates subjectivity and improves clinical confidence
- Improves patient satisfaction



CGX / CANCER RISK SCREENING

COMMON ICD-10 CODES

Breast Cancer

C50	Malignant neoplasm of breast
C50.1 - C50.9	Malignant neoplasm of breast (Other Quadrants)

Ovarian Cancer

C56.9	Adenocarcinoma / Androblastoma / Arrhenoblastoma, Neoplasm ovary- malignant / Carcinoma (malignant), Cystadenocarcinoma / Cystadenoma / Dysgerminoma, Leydig cell, Sertoli cell / Tumor: Neoplasm - unspecified
-------	---

Colorectal Cancer

C7A.02	Malignant carcinoid tumors of the colon
C00-D49	Neoplasms
C15-C26	Malignant neoplasms of digestive organs

Endometrial Cancer

C54.1	Malignant neoplasm of endometrium
C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified

Pancreatic Cancer

C25.9	Adenocarcinoma, Carcinoma (malignant)
-------	---------------------------------------

Prostate Cancer

C61	Malignant neoplasm of prostate
C63.7	Malignant neoplasm of seminal vesicle

Gastric Cancer

C16.9	Adenocarcinoma, Carcinoma (malignant), Leather bottle stomach, Tumor
-------	--

Skin Cancer

C43 - C43.9	Malignant melanoma of skin
C43.0 - C43.9	Malignant melanoma of skin (Various regions)
C44.0 - C44.9	Other malignant neoplasms of skin (Various regions)

★ Not all inclusive list



3600 S Gessner Rd Suite 110, Houston, TX 77063
Phone: 281-378-2116 | Fax: 281-466-2483
www.elitelabs.com